Corporate Deck
Presentations
06
Jun 2023
2023 ASCO | Phase I Trial of Chimeric Anti-GPC3 scFv-CD3ε Engineered T Cells (CT0180) in Patients with Advanced Hepatocellular Carcinoma
Jun 06, 2023
20
Apr 2023
2023 AACR | CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis
Apr 20, 2023
20
Jan 2023
2023 ASCO GI | A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti CLDN18.2 Monoclonal Antibody (AB011), as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors
Jan 20, 2023
11
Dec 2022
2022 ASH | Phase II Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Dec 11, 2022
29
Sep 2022
2022 CAR TCR Summit
Sep 29, 2022
05
Jun 2022
2022 ASCO | Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T‐cell therapy (CT041)
Jun 05, 2022